<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00762710</url>
  </required_header>
  <id_info>
    <org_study_id>1R01AA017184-01</org_study_id>
    <secondary_id>5R01AA017184-05</secondary_id>
    <nct_id>NCT00762710</nct_id>
  </id_info>
  <brief_title>Study of the Medication Prazosin for Alcohol Dependence</brief_title>
  <official_title>Clinical Trial of the Adrenergic Alpha-1 Antagonist Prazosin for Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Institute for Biomedical and Clinical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Puget Sound Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Institute for Biomedical and Clinical Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the drug prazosin is effective for the
      treatment of alcohol dependency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alcohol dependence (AD) afflicts nearly 10% of the US population and causes marked medical
      morbidity and mortality, marked psychiatric morbidity, increased health care costs, and lost
      work hours (Saxon, Malte, Sloan, et al., 2006; McFall, Saxon, Thaneemit-Chen, et al., 2007).
      Alcohol dependence is a biologically, genetically based disease, yet the majority of
      clinically accepted treatments are behaviorally or psychosocially based (Anton, O'Malley,
      Ciraulo, et al., 2006; Todd, Armeli, Tennen, et al., 2005). Despite the initial success of
      these treatments, 40-70% of patients relapse within the first 12 months after treatment
      (McGinnis &amp; Foege, 1993). Research is needed to develop more effective biological treatments.

      Currently, only three pharmacological treatments are FDA approved for the treatment of
      alcohol dependence and all are sub-optimal. None of these medications directly target
      noradrenergic brain systems. Recent advances in understanding the neurobiology of substance
      dependence and relapse support the notion that adrenergic systems play a critical role in
      these processes.

      In a 6-week, double-blind, placebo-controlled pilot study, we randomized 24 participants
      without PTSD entering treatment for AD to prazosin or identical appearing placebo (Simpson et
      al., 2009). The prazosin group reported no more adverse events than the placebo group, and
      controlling for drinks per week at baseline and week number, the prazosin group reported
      fewer drinks per week in the final 3 weeks of the study. These findings led us to conduct a
      larger trial to further evaluate prazosin for AD.

      The current study is a 16-week, randomized, two group parallel-design, double-blind,
      placebo-controlled trial to evaluate the efficacy of prazosin for decreasing alcohol use and
      the subjective experience of alcohol craving in individuals without PTSD who are seeking
      treatment for AD. Following randomization, a 2-week titration period will be followed by 10
      weeks of stable dosing of prazosin or placebo. Study participants will attend study visits at
      least weekly for 12 weeks and will complete a final follow-up one month after discontinuation
      of the medication phase of the study at 16 weeks post-randomization. All study participants
      will also participate in Medical Management (MM) treatment, a behavioral intervention that
      has demonstrated efficacy as a behavioral platform for treatment of AD (Anton, O'Malley,
      Ciraulo, et al., 2006). Study participants will not be involved in other professional
      counseling or substance abuse treatment during their study involvement, though 12-step
      meeting attendance is encouraged during MM. Daily monitoring of alcohol craving, alcohol use,
      other substance craving and substance use, medication compliance, and key psychiatric
      symptoms via toll-free telephone calls to an Interactive Voice Response (IVR) system will
      continue throughout the 16-week study. Outcome measures will address alcohol use and craving
      and include IVR reports of craving and use, the TLFB for alcohol use, Penn Alcohol Craving
      Scale (PACS), Patient Health Questionnaire-9 (depression), urine toxicology analysis (UDA),
      and Breathalyzer readings.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2008</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol Consumption</measure>
    <time_frame>12 weeks</time_frame>
    <description>At the baseline and final medication visits, the Form 90 (19) was used to assess alcohol and drug use for the preceding 90-day period</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>1 - Prazosin Medication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following randomization, participants in this arm will receive a 2-week titration of Prazosin followed by 10 weeks of stable dosing of Prazosin. They will also attend study visits at least weekly for 12 weeks and will complete a final follow-up one month after discontinuation of the medication phase of the study at 16 weeks post-randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 - Placebo Medication</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Following randomization, participants in this arm will receive a 2-week titration of placebo followed by 10 weeks of stable dosing of placebo. They will also attend study visits at least weekly for 12 weeks and will complete a final follow-up one month after discontinuation of the medication phase of the study at 16 weeks post-randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prazosin medication</intervention_name>
    <description>Form: Prazosin will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg</description>
    <arm_group_label>1 - Prazosin Medication</arm_group_label>
    <other_name>Minipress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo medication</intervention_name>
    <description>Form: Placebo will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg</description>
    <arm_group_label>2 - Placebo Medication</arm_group_label>
    <other_name>No other intervention names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current primary DSM-IV diagnosis of alcohol dependence(AD)

          -  Heavy drinking in the last 30 days

          -  At least 18 years of age

          -  Good general medical health (see Exclusion Criteria below)

          -  Capacity to provide informed consent

          -  English fluency and literacy

        Exclusion Criteria:

          -  Psychiatric/behavioral: current post-traumatic stress disorder(PTSD); psychiatric
             disorder requiring any medication other than anti-depressants; currently taking
             disulfiram, acamprosate, or naltrexone or planning to take any of these medications
             during the 12-week medication phase of the study; current dependence on any other
             psychoactive substance other than nicotine or cannabis; a current diagnosis of opioid
             abuse, use of any opioid- containing medications or benzodiazepines during the
             previous month, or UDA positive for opioids, benzodiazepines, or sedative hypnotics.

          -  Medical: significant acute or chronic medical illness; women who are pregnant, nursing
             infant(s), or of childbearing potential and not using a contraceptive method judged by
             the study physician or PA to be effective; signs or symptoms of alcohol withdrawal at
             the time of initial consent

          -  Legal involvement that could interfere with study treatment. Individuals court ordered
             for treatment will not be eligible to participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tracy L Simpson, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Puget Sound Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Saxon AJ, Malte CA, Sloan KL, Baer JS, Calsyn DA, Nichol P, Chapko MK, Kivlahan DR. Randomized trial of onsite versus referral primary medical care for veterans in addictions treatment. Med Care. 2006 Apr;44(4):334-42.</citation>
    <PMID>16565634</PMID>
  </reference>
  <reference>
    <citation>McFall M, Saxon AJ, Thaneemit-Chen S, Smith MW, Joseph AM, Carmody TP, Beckham JC, Malte CA, Vertrees JE, Boardman KD, Lavori PW. Integrating smoking cessation into mental health care for post-traumatic stress disorder. Clin Trials. 2007;4(2):178-89.</citation>
    <PMID>17456521</PMID>
  </reference>
  <reference>
    <citation>Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A; COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006 May 3;295(17):2003-17.</citation>
    <PMID>16670409</PMID>
  </reference>
  <reference>
    <citation>Todd M, Armeli S, Tennen H, Carney MA, Ball SA, Kranzler HR, Affleck G. Drinking to cope: a comparison of questionnaire and electronic diary reports. J Stud Alcohol. 2005 Jan;66(1):121-9.</citation>
    <PMID>15830912</PMID>
  </reference>
  <reference>
    <citation>McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA. 1993 Nov 10;270(18):2207-12.</citation>
    <PMID>8411605</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <results_first_submitted>October 18, 2018</results_first_submitted>
  <results_first_submitted_qc>June 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2020</results_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcohol</keyword>
  <keyword>Abuse</keyword>
  <keyword>Use</keyword>
  <keyword>Disorder</keyword>
  <keyword>Dependence</keyword>
  <keyword>Symptoms</keyword>
  <keyword>Alcoholic</keyword>
  <keyword>Alcoholism</keyword>
  <keyword>Prazosin</keyword>
  <keyword>Drug</keyword>
  <keyword>Medicine</keyword>
  <keyword>Medication</keyword>
  <keyword>Treatment</keyword>
  <keyword>Study</keyword>
  <keyword>Placebo</keyword>
  <keyword>Medical</keyword>
  <keyword>Management</keyword>
  <keyword>Craving</keyword>
  <keyword>Consumption</keyword>
  <keyword>Binge</keyword>
  <keyword>Drinking</keyword>
  <keyword>Drink</keyword>
  <keyword>Heavy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prazosin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 9, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT00762710/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began in January 2008 and ended June 2014. Six hundred and one people responding to flyers and newspaper advertisements and contacted the study, 151 provided informed consent, and 19 women and 73 men (N = 92) were randomized. Both civilian and veteran participants were seen in an outpatient VA clinic.</recruitment_details>
      <pre_assignment_details>Of the 151 consented into the study, 59 did not go onto be randomized because of the following:
Declined after screen (N=11) (includes missing baseline/first medication appointment) Ineligible at screen (N=48)
PTSD (N=11)
Acute illness (N=7)
Drug dependence (N=4)
Drinking inclusion not met (N=20)
Other (N=6)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Prazosin</title>
          <description>Prazosin medication
Prazosin medication: Form: Prazosin will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo medication
Placebo medication: Form: Placebo will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prazosin</title>
          <description>Prazosin medication
Prazosin medication: Form: Prazosin will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo medication
Placebo medication: Form: Placebo will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.3" spread="9.8"/>
                    <measurement group_id="B2" value="49.1" spread="9.5"/>
                    <measurement group_id="B3" value="48.1" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Alcohol Consumption</title>
        <description>At the baseline and final medication visits, the Form 90 (19) was used to assess alcohol and drug use for the preceding 90-day period</description>
        <time_frame>12 weeks</time_frame>
        <population>Providing baseline and last week of medication information for all participants that completed the titration period (40 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Prazosin</title>
            <description>Prazosin medication
Prazosin medication: Form: Prazosin will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo medication
Placebo medication: Form: Placebo will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Consumption</title>
          <description>At the baseline and final medication visits, the Form 90 (19) was used to assess alcohol and drug use for the preceding 90-day period</description>
          <population>Providing baseline and last week of medication information for all participants that completed the titration period (40 in each group).</population>
          <units>percentage of days heavy drinking</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline % Days Heavy Drinking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8" spread="29.1"/>
                    <measurement group_id="O2" value="66.5" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final medication week % Days Heavy Drinking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="22.8"/>
                    <measurement group_id="O2" value="22.6" spread="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were monitored for adverse events after they started taking medications and about one month after they discontinued the medications. Because a few participants withdrew from the study after the baseline, where medications were dispensed, adverse events were monitored from one week to 16 weeks, depending on the length of participants' participation in the study.</time_frame>
      <desc>Participants were queried at every study visit with regard to potential adverse events and underwent clinical safety checks (e.g., sitting and stand blood pressures) at each visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Prazosin</title>
          <description>Prazosin medication
Prazosin medication: Form: Prazosin will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo medication
Placebo medication: Form: Placebo will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>medical hospitalization</sub_title>
                <description>placebo participant hospitalized for acute pancreatitis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Medical hospitalization</sub_title>
                <description>prazosin participant admitted to hospital for infected wisdom tooth</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Placebo participant committed suicide.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>inpatient alcohol detoxification</sub_title>
                <description>two prazosin participants were hospitalized for acute alcohol withdrawal</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Lack of knowledge of optimal dosing for prazosin and medication adherence (medication adherence was suboptimal).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Tracy Simpson</name_or_title>
      <organization>VA Puget Sound</organization>
      <phone>(206) 277-3337</phone>
      <email>Tracy.Simpson@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

